Zwitterion-functionalized hollow mesoporous Prussian blue nanoparticles for targeted and synergetic chemo-photothermal treatment of acute myeloid leukemia.

Journal of Materials Chemistry. B, Materials for Biology and Medicine
Huiyuan BaiYu Zhang

Abstract

Multifunctional drug delivery systems combining two or more therapies have a wide-range of potential for high efficacy tumor treatment. Herein, we designed a novel hollow mesoporous Prussian blue nanoparticles (HMPBs)-based platform for targeted and synergetic chemo-photothermal treatment of acute myeloid leukemia (AML). The HMPBs were first loaded with the anticancer drugs daunorubicin (DNR) and cytarabine (AraC), and were subsequently coated with polyethylenimine (PEI) through electrostatic adsorption. Then, zwitterionic sulfobetaine (ZS) and CXCR4 antagonist peptide E5 were modified onto the surface of the nanoparticles via covalent bonding to fabricate a nanoplatform (denoted as HMPBs(DNR + AraC)@PEI-ZS-E5). The nanoplatform showed excellent photothermal effects, superior photothermal stability, reduced nonspecific protein adsorption, efficient targeting capability, a constant hydrodynamic diameter and good biocompatibility. Additionally, a laser-responsive drug release pattern was observed. In vitro results indicated that the nanoplatform could achieve active targeting and remarkable chemo-photothermal synergetic therapeutic effects, showcasing its great potential in AML treatment.

References

Aug 25, 2009·Advanced Drug Delivery Reviews·Francesca Greco, María J Vicent
Jul 25, 2013·Advanced Drug Delivery Reviews·Arun K IyerMansoor M Amiji
Jul 26, 2013·Chemical Communications : Chem Comm·Xiaolong LiangMaomao Huang
Apr 24, 2014·Langmuir : the ACS Journal of Surfaces and Colloids·Joseph B Schlenoff
Aug 20, 2014·Accounts of Chemical Research·Akshaya Bansal, Yong Zhang
Aug 22, 2014·Leukemia·G Montalban-Bravo, G Garcia-Manero
Sep 27, 2014·Chemical Reviews·Liang ChengZhuang Liu
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Feb 27, 2016·Journal of the American Chemical Society·Wei ZhangYu Zhang
Feb 12, 2017·Materials Science & Engineering. C, Materials for Biological Applications·Danuta PentakZygmunt H Zawada
Jul 18, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jianfeng GuoCaitriona M O'Driscoll
Dec 17, 2019·Advanced Functional Materials·Ki Young ChoiPaula T Hammond
May 19, 2020·Journal of Biomaterials Science. Polymer Edition·Ruijuan ZuChen Wang
Sep 20, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Doudou YanHaiyan Xu

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

FlowJo
GraphPad Prism

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.